Member Info for Aether

Is it just housekeeping or does it have a real impact on our understanding of the clinical trial?

Was this really a big update?

Why are they doing it?

It's also important from a clinical perspective. For example, when considering the best time to administer Synairgen.

From a commercial perspective, this is very useful for Synairgen. Thank you, Titania.

I was wondering whether there were examples of a large pharmaceutical company buying up a smaller company on the basis of commercially useful data. After a bit of research it turns out there are. Peace.

If there are any gems in the data from either ACTIV-2 P2 or SPRINTER 3, the share price increase.

The question is how much?

£1?

Polygon will use their position to push for either an EUA or a TO by a Big Pharma.

They won't wait around for another trial.

Mea culpa.

All the Golden Rules were ignored.

Don't invest in AIM.

Don't invest in a drug trial for a company with no other product on sale.

Don't invest more than you can afford to lose.

Be aware of self-reinforcing echo chambers: The opinion of anonymous randoms isn't fact.

Be aware of greed and talk of Bentleys, etc, an indication of Walter Mitty delusional thinking, means you're not in a good place.

The who experience caused a way of thinking confidence tricksters and cults induce to cloud rational judgement.

The irony is the drug is effective but not for the endpoints chosen in that trial.

Now we wait to see if the original investment can be recouped.

Our immediate hopes rest on:

- getting on another trial(s).
- SPRINTER P3 deep dive and long Covid analysis throw up some gems.
- ACTIV-2 P2 data being very good.

SNG is an excellent drug. It will make money. The question is when.

Thank you, Wigster.

I'm not interested in a EUA.

What would the share price be if it can show statistical significance on important measures, primarily, reduction in death & excellent safety profile of SNG001 primarily?

What would a Big Pharma pay for that?

£1?

Our immediate hopes rest on:

- getting on another trial(s).
- SPRINTER P3 deep dive and long Covid analysis throw up some gems.
- ACTIV-2 P2 data being very good.

This is now about patience and waiting.

How much would SNG be worth to a Big Pharma if there are some gems in the data?

£1?

The question is what did SNG tell Polygon over the weekend that caused them to continue buying after the RNS?

What were the trends in the data?

Why buy up to 25%+ to prevent a low sp TO?

BeforeGolfs comment about how it is possible to analyse the data by removing specific irrelevant categories to look for statistical significance was very interesting.

Will they combine the data from both trials when they analyse the data?

If there are gems in the data, how much would a Big Pharma be prepared to pay for SNG?

Polygon have NOT thrown the towel in.

They continue to invest after the RNS.

They are doing this to protect their position and prevent a low sp TO.

If they had thrown the towel in, they would not bother doing this.

You have been emotionally traumatised, as many of us have, by the RNS on 21 February.

Our immediate hopes rest on:

- getting on another trial(s).
- SPRINTER P3 deep dive and long Covid analysis throw up some gems.
- ACTIV-2 P2 data being very good.

SNG is an excellent drug. It will make money. The question is when.

My own hope is that there are gems in the data and Polygon will use their position to negotiate a sale to a Big Pharma.

Peace.

This is about patience and waiting now.

I suspect TLW is tempering his expectations. This is wise.

The sp collapse and the misinterpreted company RNS are an emotional rollercoaster.

He is tempering his expectations so if there are gems in the data this is good on the other hand if the data is less certain then it is less of hammerblow.

Our immediate hopes rest on:

- getting on another trial(s).
- SPRINTER P3 deep dive and long Covid analysis throw up some gems.
- ACTIV-2 P2 data being very good.

SNG is an excellent drug. It will make money. The question is when.

My own hope is that there are gems in the data and Polygon will use their position to negotiate a sale to a Big Pharma.

Our immediate hopes rest on:

- getting on another trial(s).
- SPRINTER P3 deep dive and long Covid analysis throw up some gems.
- ACTIV-2 P2 data being very good.

If these are are positive, we will recoup our investment.

Polygon will not sit on their hands.

Does anyone have a serious answer?

Polygon will want to maximise profits as soon as possible if the data from ACTIV-2 P2 and SPRINTER 3 contains any gems.